We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hospitality Properties Trust (Nasdaq: HPT) today announced a regular quarterly common share distribution of $0.51 per common share ($2.04 per share per year). This distribution will be paid...
http://www.tickerreport.com/banking-finance/497101/hyperion-therapeutics-upgraded-to-buy-at-zacks-hptx/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hyperion Therapeutics, Inc. Juan E. Monteverde, a...
http://www.fool.com/investing/general/2015/04/18/3-top-healthcare-stocks-surging-higher-this-year.aspx?source=eptadnlnk0000002
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. ("Hyperion” or "the Company...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Hyperion Therapeutics, Inc. (NASDAQ: HPTX) (“Hyperion” or “the Company”) in connection...
Law Offices of Marc S. Henzel Announces Securities Class Action Periods PR Newswire MERION, Pa., April 7, 2015 MERION, Pa., April 7, 2015 /PRNewswire/ -- The Law Offices of Marc S. Henzel...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
HYPERION THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Hyperion Therapeutics, Inc. Over the Proposed Sale of the Company to Horizon Pharma, Plc...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions